Shire Orphan Therapies GmbH, based in Berlin, is a 100% subsidiary of Shire Deutschland Investments GmbH and since 2018 has exclusively licensed out the rights to the product Firazyr®. The company has no employees and production and distribution of Firazyr® are carried out by other group companies that receive a fixed remuneration. In the fiscal year 2024/2025 SOT reported sales of EUR 34,313,094.28 and loan receivables from affiliated companies of EUR 315,692,420.39. Since January 1, 2018 there has been a profit transfer agreement with Shire Deutschland Investments GmbH; the reported net profit of EUR 39,934,866.96 for the year was transferred to SDI under that agreement.
Die Entwicklung, die Herstellung und der Vertrieb von chemischen und biochemischen Produkten und Wirkstoffen und von Pharmazeutika und Diagnostika mit Ausnahme erlaubnispflichtiger Herstellungstätigkeiten.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Berlin (Charlottenburg) Local Court, HRB 136561 (as of 28 August 2026)
Source: German Commercial Register (Handelsregister) Berlin (Charlottenburg) Local Court, HRB 136561 (as of 28 August 2026)
Sign in to download data
Source: German Commercial Register (Handelsregister) Berlin (Charlottenburg) Local Court, HRB 136561 (as of 28 August 2026)
Sign in to view detailed salary and cost trends.
